Please assess the completion status of the following clinical trial:

Trial Title: Ataluren for Nonsense Mutation Methylmalonic Acidemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~* Ability to provide written informed consent (parental/guardian consent if applicable)/assent (if applicable)~* Age ≥2 years~* Phenotypic evidence of methylmalonic acidemia (MMA) based on the presence of characteristic clinical symptoms or signs and an elevated plasma MMacid level (\>0.27 micromole/liter (umol/L)~* Presence of a nonsense mutation in at least 1 allele of the mutase (mut), Cobalamin A (cblA), or Cobalamin B (cblB) gene~* Glomerular filtration rate ≥30 milliliters (mL)/minutes/1.73 meters squared (m\^2), serum aminotransferase values ≤2.5\*the upper limit of normal, serum bilirubin ≤1.5\*the upper limit of normal, plasma adrenocorticotropic (ACTH) within normal limits~* Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures~Major Exclusion Criteria:~* Known hypersensitivity to any of the ingredients or excipients of the study drug~* Any change in chronic treatment for MMA within 2 months prior to start of screening laboratory assessments~* Episode of metabolic decompensation within 1 month prior to start of Screening laboratory assessments~* History of organ transplantation~* Ongoing dialysis for renal dysfunction

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ataluren (Type: EXPERIMENTAL): Cycle 1: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 5 mg/kg (morning), 5 mg/kg (midday), and 10 mg/kg (evening); there will then be an interval of 21 up to 42 days without treatment.~Cycle 2: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening); there will then be an interval of 14 days without treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).